The FDA has denied Eli Lilly's appeal of the agency's ruling requiring it to conduct an additional three-year study of ruboxistaurin mesylate (Arxxant) before it can be approved for treating diabetic retinopathy (DR).
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.